BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25051062)

  • 1. The association of uremic toxins and inflammation in hemodialysis patients.
    Hsu HJ; Yen CH; Wu IW; Hsu KH; Chen CK; Sun CY; Chou CC; Chen CY; Tsai CJ; Wu MS; Lee CC
    PLoS One; 2014; 9(7):e102691. PubMed ID: 25051062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between uremic toxins and depression in patients with chronic kidney disease undergoing maintenance hemodialysis.
    Hsu HJ; Yen CH; Chen CK; Wu IW; Lee CC; Sun CY; Chang SJ; Chou CC; Hsieh MF; Chen CY; Hsu CY; Tsai CJ; Wu MS
    Gen Hosp Psychiatry; 2013; 35(1):23-7. PubMed ID: 23044245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.
    Viaene L; Meijers BK; Bammens B; Vanrenterghem Y; Evenepoel P
    Perit Dial Int; 2014; 34(1):71-8. PubMed ID: 24179107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor.
    Madero M; Cano KB; Campos I; Tao X; Maheshwari V; Brown J; Cornejo B; Handelman G; Thijssen S; Kotanko P
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):394-402. PubMed ID: 30755453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoxyl sulfate, not P-cresyl sulfate, is associated with advanced glycation end products in patients on long-term hemodialysis.
    Lin CJ; Lin J; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Kidney Blood Press Res; 2015; 40(2):121-9. PubMed ID: 25833743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal-related uremic toxins in peritoneal dialysis: a pilot study with a 5-year follow-up.
    Lin CJ; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Arch Med Res; 2013 Oct; 44(7):535-41. PubMed ID: 24055267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in Dialysis Efficacy Have Limited Effects on Protein-Bound Uremic Toxins Plasma Levels over Time.
    Krieter DH; Kerwagen S; Rüth M; Lemke HD; Wanner C
    Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30654454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.
    Lin CJ; Wu V; Wu PC; Wu CJ
    PLoS One; 2015; 10(7):e0132589. PubMed ID: 26173073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.
    Shafi T; Sirich TL; Meyer TW; Hostetter TH; Plummer NS; Hwang S; Melamed ML; Banerjee T; Coresh J; Powe NR
    Kidney Int; 2017 Dec; 92(6):1484-1492. PubMed ID: 28739139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Divinylbenzenic Resin in Removing Indoxyl Sulfate and P-Cresol Sulfate in Hemodialysis Patients: Results From an In Vitro Study and An In Vivo Pilot Trial (xuanro4-Nature 3.2).
    Rocchetti MT; Cosola C; di Bari I; Magnani S; Galleggiante V; Scandiffio L; Dalfino G; Netti GS; Atti M; Corciulo R; Gesualdo L
    Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32164382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.
    Yamamoto S; Sato M; Sato Y; Wakamatsu T; Takahashi Y; Iguchi A; Omori K; Suzuki Y; Ei I; Kaneko Y; Goto S; Kazama JJ; Gejyo F; Narita I
    Artif Organs; 2018 Jan; 42(1):88-93. PubMed ID: 28703401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.
    Lee CT; Hsu CY; Tain YL; Ng HY; Cheng BC; Yang CC; Wu CH; Chiou TT; Lee YT; Liao SC
    Blood Purif; 2014; 37(1):76-83. PubMed ID: 24576840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial.
    Sirich TL; Fong K; Larive B; Beck GJ; Chertow GM; Levin NW; Kliger AS; Plummer NS; Meyer TW;
    Kidney Int; 2017 May; 91(5):1186-1192. PubMed ID: 28089366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing the removal of protein-bound uremic toxins by liposome-supported hemodialysis.
    Shi Y; Wang Y; Ma S; Liu T; Tian H; Zhu Q; Wang W; Li Y; Ding F
    Artif Organs; 2019 May; 43(5):490-503. PubMed ID: 30375673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations among total p-cresylsulfate, indoxyl sulfate and hippuric acid levels with hemodialysis quality indicators in maintenance hemodialysis patients.
    Lu YC; Wu CC; Tsai IT; Hung WC; Lee TL; Hsuan CF; Yu TH; Wei CT; Chung FM; Lee YJ; Wang CP
    Clin Chim Acta; 2021 May; 516():83-91. PubMed ID: 33508250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis.
    Iguchi A; Yamamoto S; Oda A; Tanaka K; Kazama JJ; Saeki T; Yamazaki H; Ishioka K; Suzutani T; Narita I
    Clin Exp Nephrol; 2020 Aug; 24(8):725-733. PubMed ID: 32285213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
    Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
    Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term variation of serum levels of uremic toxins in patients treated by post-dilution high volume on-line hemodiafiltration in comparison to standard low-flux bicarbonate dialysis: results from the REDERT study.
    Panichi V; Rocchetti MT; Scatena A; Rosati A; Migliori M; Pizzarelli F; Gesualdo L;
    J Nephrol; 2017 Aug; 30(4):583-591. PubMed ID: 28337716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study.
    Rossi M; Campbell K; Johnson D; Stanton T; Pascoe E; Hawley C; Dimeski G; McWhinney B; Ungerer J; Isbel N
    Nutr Metab Cardiovasc Dis; 2014 Sep; 24(9):1035-42. PubMed ID: 24880738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.